Search Results
You are looking at 1 - 9 of 9 items for
- Author: M Schmidt x
- Refine by access: All content x
Search for other papers by M Schmidt in
Google Scholar
PubMed
Search for other papers by C Renner in
Google Scholar
PubMed
Search for other papers by G Loffler in
Google Scholar
PubMed
In fibroblasts derived from human adipose tissue, aromatase induction is observed after exposure to 1 microM cortisol in the presence of serum or platelet-derived growth factor (PDGF). Progesterone suppresses this induction in a dose-dependent manner, 10 microM resulting in complete inhibition. A reduced cortisol concentration (0.1 microM) concomitantly reduces the progesterone concentration required for effective inhibition (10-100 nM). This effect of progesterone is specific, as neither the release of cellular enzymes nor aromatase induction by dibutyryl-cAMP, which acts independently from cortisol, are affected. However, the inhibitory effect of progesterone requires its presence throughout the induction period. Kinetic studies in intact cells reveal a reduced number of aromatase active sites upon progesterone treatment, whereas progesterone at near-physiological concentration (100 nM) does not inhibit aromatase activity in isolated microsomes. Semi-quantitative reverse transcriptase PCR analysis shows reduced amounts of aromatase mRNA in progesterone-treated cells, indicating specific inhibition of the glucocorticoid-dependent pathway of aromatase induction. The inhibitory effect of progesterone is not blocked by the anti-progestin ZK114043, excluding action via progesterone receptors and indicating competition for the glucocorticoid receptor. Progesterone must be considered a potential physiological inhibitor of glucocorticoid-dependent aromatase induction in adipose tissue. It is proposed that it is a suppressor of aromatase induction in adipose tissue in premenopausal women.
Search for other papers by M Schmidt in
Google Scholar
PubMed
Search for other papers by M Kreutz in
Google Scholar
PubMed
Search for other papers by G Loffler in
Google Scholar
PubMed
Search for other papers by J Scholmerich in
Google Scholar
PubMed
Search for other papers by RH Straub in
Google Scholar
PubMed
Dehydroepiandrosterone (DHEA) is a ubiquitous adrenal hormone with immunomodulatory effects such as inhibition of the production of monokines. Whether DHEA itself or the downstream steroids are the immunomodulatory effector hormones in target cells is not known. In this study, we investigated the conversion of DHEA to downstream steroid hormones in target macrophages. Within 1 day of culture with radiolabeled DHEA, monocyte-derived macrophages converted DHEA to significant amounts of Delta5-derivatives such as 16OH-DHEA, 3beta, 17beta-androstenediol (A'diol), and 3beta,16alpha, 17beta-androstenetriol (A'triol). However, the production of Delta4-steroids (androstenedione (A'dione), testosterone (T), and 16OH-T) and estrogens (estrone, estradiol, and estriol) was relatively low. Further cultivation of macrophages for 5 days with radiolabeled DHEA resulted in a significant (P<0.05) increase of the molar amounts of A'triol (P=0.012), 16OH-T (P=0.008), and estriol (P=0.003). In contrast to monocyte-derived macrophages, monocytes did not express aromatase mRNA, which was demonstrated by RT-PCR (P<0.01). Furthermore, DHEA in macrophages significantly inhibited one of the downstream converting enzymes, the aromatase, which was not demonstrated in the presence of the typical macrophage activator, lipopolysaccharide (LPS) (P<0.01). In conclusion, conversion of DHEA to physiologically relevant amounts of Delta5- and Delta4-steroids and estrogens was demonstrated in monocyte-derived macrophages. The conversion depends on maturation of monocytes and local factors such as the presence of LPS. The conversion of DHEA leads to an increase of downstream effector hormones in target macrophages which may be an important factor for local immunomodulation.
Search for other papers by Nicole Uschold-Schmidt in
Google Scholar
PubMed
Search for other papers by Daniel Peterlik in
Google Scholar
PubMed
Search for other papers by Andrea M Füchsl in
Google Scholar
PubMed
Department of Behavioural and Molecular Neurobiology, Clinic for Psychosomatic Medicine and Psychotherapy, University of Regensburg, 93053 Regensburg, Germany
Search for other papers by Stefan O Reber in
Google Scholar
PubMed
Chronic subordinate colony (CSC) housing for 19 days results in unaffected basal morning corticosterone (CORT) levels despite a pronounced increase in adrenal mass, likely mediated by an attenuation of adrenal corticotropin (ACTH) responsiveness. Given that the pronounced increase in basal morning plasma CORT levels returns to baseline as early as 48 h after the start of CSC, it is likely that the attenuated ACTH responsiveness develops already during this initial phase. This was tested in the present study. In line with previous findings, basal morning plasma CORT levels were elevated following 10 h, but not 48 h, of CSC exposure. Basal morning plasma ACTH concentrations and relative in vivo adrenal CORT content were increased following 10 h and to a lesser extent following 48 h of CSC exposure, positively correlating. Relative in vitro adrenal CORT secretion in response to ACTH (100 nM) and kidney protein expression of 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) were unaffected following both time points. Adrenal mRNA expression of key steroidogenic enzymes was unaffected/decreased following 10 h and unaffected/increased following 48 h of CSC exposure. Together, our findings suggest that basal plasma hypercorticism during the initial CSC phase is mainly prevented by an attenuation of pituitary ACTH release. An increased absolute adrenal weight following 10 h, but not 48 h, of CSC exposure indicates that restoration of normal adrenal mass also adds to a lesser extent to prevent basal hypercorticism. A contributing role of alterations in enzymatic CORT degradation and steroidogenic enzyme availability is likely, but has to be further addressed in future studies.
Search for other papers by A. A. SIMPSON in
Google Scholar
PubMed
Search for other papers by M. H. W. SIMPSON in
Google Scholar
PubMed
Search for other papers by Y. N. SINHA in
Google Scholar
PubMed
Search for other papers by G. H. SCHMIDT in
Google Scholar
PubMed
In spite of the importance of prolactin and adrenal corticosteroids in the normal control of the mammary gland (Cowie & Tindal, 1971) there has been no report of their simultaneous measurement in rat plasma during pregnancy and lactation. There is no agreement on the pattern of change in corticosteroid concentration at the time of lactogenesis and parturition (Gala & Westphal, 1965; Kuhn, 1969).
Primiparous CFE strain rats, allotted randomly to groups on day 0 of pregnancy, were decapitated without prior disturbance within 1 min after removal from their cage, between 08.30 and 09.30 h. Plasma was stored at −20 °C, total body weight after bleeding and adrenal weight were recorded. The day on which a vaginal plug was found and the day of parturition were designated day 0 of pregnancy and lactation respectively. Litter size was adjusted to six on day 0 of lactation.
Plasma prolactin concentration was assayed in
Search for other papers by E. D. Schmidt in
Google Scholar
PubMed
Search for other papers by E. D. L. Schmidt in
Google Scholar
PubMed
Search for other papers by R. van der Gaag in
Google Scholar
PubMed
Search for other papers by R. Ganpat in
Google Scholar
PubMed
Search for other papers by L. Broersma in
Google Scholar
PubMed
Search for other papers by P. A. J. de Boer in
Google Scholar
PubMed
Search for other papers by A. F. M. Moorman in
Google Scholar
PubMed
Search for other papers by W. H. Lamers in
Google Scholar
PubMed
Search for other papers by W. M. Wiersinga in
Google Scholar
PubMed
Search for other papers by L. Koornneef in
Google Scholar
PubMed
ABSTRACT
The correlation between the occurrence of Graves' ophthalmopathy and Graves' hyperthyroidism may indicate a role for tri-iodothyronine (T3) hormone in the pathogenesis of Graves' ophthalmopathy. In Graves' ophthalmopathy the recti eye muscles are greatly enlarged whereas skeletal muscles seem unaffected. The distribution of the nuclear T3 receptor was studied in normal human and rat eye and skeletal muscles with immunohistochemistry using mouse (monoclonal) antibodies, and by in-situ hybridization for the detection of mRNA encoding the T3-receptor protein.
Nuclear staining with T3-receptor antibodies was found in all types of tissues studied. Cytoplasmic staining occurred predominantly in the muscle fibres of the orbital layer of the eye muscles and was generally absent or very low in skeletal muscle fibres and hepatocytes. Immunostaining could be inhibited by preabsorbing the antibodies with bacterially expressed T3-receptor protein, implying specificity. The presence of nuclear and cytoplasmic hormonefree T3 receptor sites was indicated after preincubation of sections with T3 hormone: T3-receptor immunostaining decreased and T3-hormone staining increased. In-situ hybridization clearly revealed the presence of α-1 and β-1 forms of the T3-receptor mRNA in liver, skeletal muscles, and orbital and intermediate layers of the eye muscles.
The data demonstrate the presence of T3 hormone-receptor molecules in the extraocular and skeletal muscles. The different susceptibilities of these muscles to Graves' hyperthyroidism may relate to the quantitative differences in T3 hormone-receptor distribution.
Journal of Endocrinology (1992) 133, 67–74
Search for other papers by B Shan in
Google Scholar
PubMed
Search for other papers by C Schaaf in
Google Scholar
PubMed
Search for other papers by A Schmidt in
Google Scholar
PubMed
Search for other papers by K Lucia in
Google Scholar
PubMed
Search for other papers by M Buchfelder in
Google Scholar
PubMed
Search for other papers by M Losa in
Google Scholar
PubMed
Search for other papers by D Kuhlen in
Google Scholar
PubMed
Search for other papers by J Kreutzer in
Google Scholar
PubMed
Neuroendocrinology Group, Department of Neurosurgery, Department of Neurosurgery, Department of Neurosurgery, Laboratorio de Fisiología y Biología Molecular, IBioBA–CONICET, Max Planck Institute of Psychiatry, Kraepelinstraße 10, D-80804 Munich, Germany
Search for other papers by M J Perone in
Google Scholar
PubMed
Neuroendocrinology Group, Department of Neurosurgery, Department of Neurosurgery, Department of Neurosurgery, Laboratorio de Fisiología y Biología Molecular, IBioBA–CONICET, Max Planck Institute of Psychiatry, Kraepelinstraße 10, D-80804 Munich, Germany
Search for other papers by E Arzt in
Google Scholar
PubMed
Search for other papers by G K Stalla in
Google Scholar
PubMed
Search for other papers by U Renner in
Google Scholar
PubMed
Curcumin (diferuloylmethane), a polyphenolic compound derived from the spice plant Curcuma longa, displays multiple actions on solid tumours including anti-angiogenic effects. Here we have studied in rodent and human pituitary tumour cells the influence of curcumin on the production of hypoxia inducible factor 1α (HIF1A) and vascular endothelial growth factor A (VEGFA), two key components involved in tumour neovascularisation through angiogenesis. Curcumin dose-dependently inhibited basal VEGFA secretion in corticotroph AtT20 mouse and lactosomatotroph GH3 rat pituitary tumour cells as well as in all human pituitary adenoma cell cultures (n=32) studied. Under hypoxia-mimicking conditions (CoCl2 treatment) in AtT20 and GH3 cells as well as in all human pituitary adenoma cell cultures (n=8) studied, curcumin strongly suppressed the induction of mRNA synthesis and protein production of HIF1A, the regulated subunit of the hypoxia-induced transcription factor HIF1. Curcumin also blocked hypoxia-induced mRNA synthesis and secretion of VEGFA in GH3 cells and in all human pituitary adenoma cell cultures investigated (n=18). Thus, curcumin may inhibit pituitary adenoma progression not only through previously demonstrated anti-proliferative and pro-apoptotic actions but also by its suppressive effects on pituitary tumour neovascularisation.
Search for other papers by S Schmidt in
Google Scholar
PubMed
Search for other papers by A Hommel in
Google Scholar
PubMed
Search for other papers by V Gawlik in
Google Scholar
PubMed
Search for other papers by R Augustin in
Google Scholar
PubMed
Search for other papers by N Junicke in
Google Scholar
PubMed
Search for other papers by S Florian in
Google Scholar
PubMed
Search for other papers by M Richter in
Google Scholar
PubMed
Search for other papers by D J Walther in
Google Scholar
PubMed
Search for other papers by D Montag in
Google Scholar
PubMed
Search for other papers by H-G Joost in
Google Scholar
PubMed
Search for other papers by A Schürmann in
Google Scholar
PubMed
Deletion of glucose transporter gene Slc2a3 (GLUT3) has previously been reported to result in embryonic lethality. Here, we define the exact time point of growth arrest and subsequent death of the embryo. Slc2a3 −/− morulae and blastocysts developed normally, implanted in vivo, and formed egg-cylinder-stage embryos that appeared normal until day 6.0. At day 6.5, apoptosis was detected in the ectodermal cells of Slc2a3 −/− embryos resulting in severe disorganization and growth retardation at day 7.5 and complete loss of embryos at day 12.5. GLUT3 was detected in placental cone, in the visceral ectoderm and in the mesoderm of 7.5-day-old wild-type embryos. Our data indicate that GLUT3 is essential for the development of early post-implanted embryos.
Search for other papers by KM Kelley in
Google Scholar
PubMed
Search for other papers by KE Schmidt in
Google Scholar
PubMed
Search for other papers by L Berg in
Google Scholar
PubMed
Search for other papers by K Sak in
Google Scholar
PubMed
Search for other papers by MM Galima in
Google Scholar
PubMed
Search for other papers by C Gillespie in
Google Scholar
PubMed
Search for other papers by L Balogh in
Google Scholar
PubMed
Search for other papers by A Hawayek in
Google Scholar
PubMed
Search for other papers by JA Reyes in
Google Scholar
PubMed
Search for other papers by M Jamison in
Google Scholar
PubMed
Emerging early in chordate evolution, the IGF-regulatory axis diverged from an insulin-like predecessor into a vertebrate regulatory system specializing in cell growth activation and allied anabolic functions. Essential to the divergence of the IGF and insulin systems was an early presence of soluble IGF-binding proteins (IGFBPs), which bind IGF peptides at much higher affinity than that of the insulin receptor but at comparable affinities to that of the IGF receptor. IGFBPs have no homology with IGF receptors. Instead, IGFBPs are a derived group of proteins within a superfamily of cysteine-rich growth factors, whose members are found throughout the animal taxa. While blocking IGF actions through the insulin receptor is a fundamental role, IGFBPs evolved within the vertebrate line into centralized, 'integrators' of the endocrine growth-regulatory apparatus. IGFBPs have substantial influences on the distribution and bioavailability of IGF peptides in the cellular and physiological environments, but they have a variety of other properties. The six principal mammalian IGFBPs exhibit an array of specialized properties that appear to be derived from a complex evolutionary history (including cell membrane association, interaction with proteins that post-translationally modify them, direct IGF-independent effects on cells, and others) and they are regulated by a diversity of 'outside' factors (e.g. other hormones, metabolic status, stress). Thus, IGFBPs are multifunctional integrators having diverse physiological 'agendas'. Much less is known about IGFBPs and their properties in the other vertebrate taxa. Increasingly, however, it is being recognized that they play equally important endocrine roles, in both conserved and non-conserved ways, when compared with those currently defined in mammals. This review highlights selected 'comparative aspects' in current IGFBP research, in an attempt to view this essential group of endocrine regulators from a wider, biological perspective.
Search for other papers by E. D. Schmidt in
Google Scholar
PubMed
Search for other papers by G. van Hogerwou in
Google Scholar
PubMed
Search for other papers by R. van der Gaag in
Google Scholar
PubMed
Search for other papers by W. M. Wiersinga in
Google Scholar
PubMed
Search for other papers by G. Asmussen in
Google Scholar
PubMed
Search for other papers by L. Koornneef in
Google Scholar
PubMed
ABSTRACT
It has been suggested that the effects of dysthyroidism on resident immunocompetent cells of the extraocular muscles may play a role in the pathogenesis of Graves' ophthalmopathy. The distribution of such cells was therefore studied in extraocular muscles of rats that were made hyper- or hypothyroid by the oral administration of thyroxine or propylthiouracil respectively. Skeletal muscles were studied for comparison. The cell distributions were analysed in cryostat cross-sections subjected to a two-step immunoperoxidase method using well-characterized monoclonal antibodies against T cells, B cells, macrophages and MHC class II antigens.
The extraocular muscles of control (euthyroid) rats contained numerous macrophages, fewer MHC-II positive cells and T cells and no B cells. Differences in the distribution of immunocompetent cells were found in control rats, between skeletal and extraocular muscles as well as within the various recti eye muscles. This particular tissue distribution resembles that previously reported for human extraocular and skeletal muscles.
Quantitative analysis showed that experimental dysthyroidism only affected cell populations in the extraocular muscles. Significant effects on the number of macrophages were observed in the inferior rectus muscle of both hypo- and hyperthyroid rats, this was most pronounced in the orbital layer of the muscles. Both hyper- and hypothyroidism appear to affect local cell distributions in a tissue-specific manner. The presently observed site-dependent effects of dysthyroidism on local immunocompetent cell populations may have relevance for the differential involvement of muscular tissues in Graves' ophthalmopathy.
Journal of Endocrinology (1992) 135, 485–493
